Serous carcinoma of the fallopian tube presenting as axillary lymphadenopathy.

Serous carcinoma originating in the fallopian tube usually presents at an advanced stage with extensive pelvic disease. Palpable axillary lymphadenopathy as the initial presentation of primary fallopian tube cancer without extensive extratubal spread in the pelvis is very uncommon. We report a case of a woman with a high-grade serous carcinoma of fallopian tube origin whose initial clinical presentation was palpable axillary lymphadenopathy.

Diffuse laminar endocervical glandular hyperplasia: a case report.

Background: Diffuse laminar endocervical glandular hyperplasia is extremely rare with only 14 cases reported in the literature. Diffuse laminar endocervical glandular hyperplasia is a benign lesion that is easily confused with malignancy.

Case Report: We present a 22-year-old woman referred to our gynecologic oncology service with a 2.

Endometrial cancer--current state of the art therapies and unmet clinical needs: the role of surgery and preoperative radiographic assessment.

Endometrial carcinoma is the fourth most common cancer among women in the United States. Surgical pathologic staging has been the standard of care since 1988, which consists of analysis of collected peritoneal fluid, hysterectomy/oophorectomy, and pelvic and para-aortic lymphadenectomy. In 2005, it was further recommended that essentially all women with endometrial cancer who choose to undergo surgery have pelvic and para-aortic lymph node analysis.

Changes in embryonic development and hatching in Chionoecetes opilio (snow crab) with variation in incubation temperature.

Water temperature affects the distribution, movement, and reproductive potential of female snow crab, Chionoecetes opilio. Ovigerous females of C. opilio from the eastern Bering Sea were held at five temperatures (-1, 0, 1, 3, and 6 degrees C) in the laboratory while their embryos developed from gastrula to hatching.

Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.

Background: Bevacizumab has demonstrated activity against a variety of solid tumors, including ovarian carcinoma. However, there have not been reproducible prognostic features associated with its activity.

Cases: One patient each with recurrent, refractory well-differentiated serous-endometrioid ovarian carcinoma, micropapillary serous carcinoma of the ovary, and primary peritoneal micropapillary serous carcinoma were treated with single agent bevacizumab (15 mg/kg [DOSAGE ERROR CORRECTED] intravenously every 3 weeks).

Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix?

Objective: The goal of this study was to determine if International Federation of Obstetrics and Gynecology (FIGO) subdivision into IA1 versus IA2 is predictive of survival differences for early invasive adenocarcinoma.

Methods: The Surveillance, Epidemiology, and End-Results (SEER) Public-Use Database was used to identify all cases of IA1 and IA2 adenocarcinoma diagnosed between 1983 and 1997. A systematic literature search (MEDLINE 1966-2000) was used to identify all previously published cases.